In one paragraphArticle in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
21 authors.
Mario LeypoldMedicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Pepparedsleden 1 43183 Mölndal Sweden mario.leypold@astrazeneca.com.ORCID https://orcid.org/0000-0002-9780-6371 Lorenzo PoliMedicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Pepparedsleden 1 43183 Mölndal Sweden mario.leypold@astrazeneca.com.ORCID https://orcid.org/0000-0002-6009-6302 Max EarlMedicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Pepparedsleden 1 43183 Mölndal Sweden mario.leypold@astrazeneca.com.ORCID https://orcid.org/0009-0005-5664-378X Karolina KwapienMedicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Pepparedsleden 1 43183 Mölndal Sweden mario.leypold@astrazeneca.com.ORCID https://orcid.org/0000-0002-2003-0915 Richard J LewisMedicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Pepparedsleden 1 43183 Mölndal Sweden mario.leypold@astrazeneca.com.ORCID https://orcid.org/0000-0001-9404-8520 John J MurphyMedicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Pepparedsleden 1 43183 Mölndal Sweden mario.leypold@astrazeneca.com.ORCID https://orcid.org/0000-0001-8411-9540 Marta PassamontiMedicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Pepparedsleden 1 43183 Mölndal Sweden mario.leypold@astrazeneca.com.ORCID https://orcid.org/0000-0002-6691-4054 Lena M von SydowMedicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Pepparedsleden 1 43183 Mölndal Sweden mario.leypold@astrazeneca.com.ORCID https://orcid.org/0009-0002-4445-2255 Hikaru SekiMedicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Pepparedsleden 1 43183 Mölndal Sweden mario.leypold@astrazeneca.com.ORCID https://orcid.org/0000-0001-9663-7791 Thomas LemaitreMedicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Pepparedsleden 1 43183 Mölndal Sweden mario.leypold@astrazeneca.com.ORCID https://orcid.org/0009-0002-8710-4859 Radvile JuskaiteMedicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Pepparedsleden 1 43183 Mölndal Sweden mario.leypold@astrazeneca.com.ORCID https://orcid.org/0009-0008-1258-445X Ranganath GopalakrishnanMedicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Pepparedsleden 1 43183 Mölndal Sweden mario.leypold@astrazeneca.com.ORCID https://orcid.org/0000-0001-9825-2334 Stuart J FrancisMedicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Pepparedsleden 1 43183 Mölndal Sweden mario.leypold@astrazeneca.com.ORCID https://orcid.org/0000-0003-2810-7101 Cristina GardelliMedicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Pepparedsleden 1 43183 Mölndal Sweden mario.leypold@astrazeneca.com.ORCID https://orcid.org/0000-0003-1169-2180 Werngard CzechtizkyMedicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D AstraZeneca Pepparedsleden 1 43183 Mölndal Sweden mario.leypold@astrazeneca.com.ORCID https://orcid.org/0000-0003-4487-2399 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
A regioselective synthesis of aromatic and aliphatic aza-saccharins as cyclic sulfonimidamide derivatives is reported, starting from easily accessible aryl sulfonimidoyl fluorides and primary or secondary amines with broad functional group tolerance. The transformation is enabled by electron-withdrawing substituents and proceeds through an anionic [1,4] Fries-type rearrangement at cryogenic temperature, initiated by KHMDS-mediated
Identifiers
PMID42058823
PMCPMC13123728
What OpenQuestion holds
Textmetadata
Read underepoch 390